Experience

JEITO

• Argentina
• Business Consulting and Services
• 1 - 100 Employee

• Junior analyst - Private Equity in Biopharma

  • Nov 2022 - Present

  Jeito Capital is an investment firm dedicated to biotech and biopharma, based in France. It was founded in 2020 and is backed by French healthcare giant Sanofi. Jeito Capital focuses on clinical stage companies in diversified therapeutic areas such as immuno-oncology, ophthalmology, rare skeletal diseases, severe respiratory diseases, fibrosis and associated cancers. Jeito Capital has developed an approach focused on patient benefits, financing and accelerating cutting-edge medical innovation. Jeito supports and accompanies entrepreneurs through its multidisciplinary team of experts across the entire drug value chain, as well as through a significant capital contribution to ensure the growth of companies. Jeito thus contributes to the emergence of leaders in specific therapeutic areas and accelerates the commercialization of innovative treatments throughout the world, particularly in Europe and the United States, for the benefit of patients. Key missions: - Identifying promising startups and emerging industries for investment. - Conducting due diligence on potential investments, including financial analysis and market research. - Assisting with the preparation of investment materials, such as pitch decks and investment memos. - Participating in investment meetings and presenting recommendations to the investment team. - Monitoring the performance of portfolio companies and providing support to them as needed. - Conducting market and industry research with a focus on trends and developments. - Networking with entrepreneurs, investors, and industry experts to identify new investment opportunities.



Smart Immune

• Wellness and Fitness Services

• Project Manager - PhD Candidate (Cifre)

  • Oct 2019 - Nov 2022

  PhD in Pharmaceutical Biotechnology and Gene Therapy Allogeneic hematopoietic stem cell transplantation (HSCT) is considered as the gold standard therapeutic strategy that offers long disease-free survival and possibly a cure to patients suffering from primary immunodeficiencies as well as relapsed or refractory leukemia. However, this is achieved at the cost of important morbidity and mortality. Immune reconstitution following transplantation is a major concern, since slow or delayed reconstitution is associated with an acute risk of bacterial or viral infection. The T-cell subset, in particular, can take up to a year to rise back up to a normal level in transplanted patients. Hope for improvement of prognosis following hematopoietic stem cell transplantation lies in the possibility to reduce this window of immunodeficiency, particularly by initiating an early thymopoiesis using cells able to migrate to the thymus and to start T-cell subset reconstitution. The project has evaluated the specificity of ex vivo Human T lymphoid progenitors obtained from different hematopoietic stem cells starting materials, highlighting an overall homogeneity of cell phenotypes with slight molecular differences whose clinical impact has yet to be evaluated. By deepening existing knowledge of the different cell populations composing ex vivo generated Human T Lymphoid progenitors, the project complements the recent progress made in defining human hematopoiesis, especially with the discussion of the dogmatic opposition of innate and adaptative immunity, the newly described behaviors of ILCs, as well as the ontogenic proximity of different lineages constituted by lymphoid cells and dendritic cells. Human T lymphoid progenitors are currently investigated in different clinical trials in the US and in Europe.



Imagine Institute of Genetic Diseases

• France
• Research Services
• 200 - 300 Employee

• Intern - Research in Gene Therapy

  • Feb 2019 - Oct 2019

  Research project in the Human Lymphohematopoiesis Lab, headed by Pr Marina Cavazzana and Dr Isabelle André The research group studies underlying mechanisms of immune recovery in the context of hematopoietic stem cell transplantation in humans but also the differentiation of mouse and human stem cells towards lymphocyte lineages. Isabelle André's team has identified key steps in the production of T cells, key players of immunity generated throughout the life of an individual within the thymus. This work led to the development of an artificial thymus, which will be tested in a clinical trial to reduce the immune deficiency period after bone marrow transplantation. The internship has involved investigation of gene therapy protocols on the Human T Lymphoid Progenitors platform for various clinical applications.



Massachusetts Institute of Technology

• United States
• Higher Education
• 700 & Above Employee

• Visiting Student - Research in Neurobiology

  • Mar 2018 - Aug 2018

  Within Mriganka Sur's Lab, research project on Astrocyte involvment in Motor learning. The team has demonstrated that astrocytes play an important role in modulating synaptic plasticity and promoting motor learning. Specifically, their research has shown that astrocytes can regulate the release of neurotransmitters, alter neuronal excitability, and regulate the levels of glutamate in the synaptic cleft. Furthermore, they have found that astrocytes can be modulated by motor learning, providing a potential mechanism by which learning can occur.



PwC

• Professional Services
• 700 & Above Employee

• Financial auditor

  • Sep 2017 - Mar 2018

  Financial audit - companies in the RCHP sector (Retail, Consumer, Health & pharma) Key missions: - Examining the company's financial statements, including the balance sheet, income statement, and statement of cash flows, to ensure that they are complete and accurate. - Testing the company's internal controls over financial reporting to ensure that they are effective and compliant with relevant laws and regulations. - Reviewing the company's financial policies and procedures to ensure that they are appropriate and followed consistently. - Evaluating the company's compliance with relevant laws and regulations, including those related to pricing, reimbursement, and the promotion of specific products.



Pasteur Institute

• Government Administration
• 1 - 100 Employee

• Intern - Research in Structural Virology

  • Feb 2017 - Aug 2017

  Structural analysis of the NS1 protein in organisms infected with the dengue virus (Pr Felix Rey's lab). NS1 is a protein that is produced by the dengue virus. It is present in the blood during the acute phase of dengue infection and can be detected using a laboratory test. The presence of NS1 can be used to confirm the diagnosis of dengue infection, especially in the early stages of the illness when antibodies to the virus may not yet be detectable. According to research by Souheyla Benfrid and others, the Dengue virus NS1 protein binds to low-density lipoprotein (LDL) particles in the plasma of hospitalized dengue patients. The NS1 protein binds to both high- and low-density lipoprotein particles, but the binding of NS1 to LDL particles is stronger than the binding of NS1 to HDL particles. This indicates that LDL particles may be a potential target for developing effective treatments for dengue virus infection.



BDE AgroParisTech (student council)

• Entrepreneurship section

  • Feb 2016 - Feb 2017

  - Development of partnerships and organization of events during the year - Organization and solicitations for the Forum Vitae 2016 (AgroParisTech Enterprise Forum) with : . 70 companies. . 5 Presentations & Business Lunch. . Job interview simulations. - AgroParisTech Ambassador for PwC - Development of partnerships and organization of events during the year - Organization and solicitations for the Forum Vitae 2016 (AgroParisTech Enterprise Forum) with : . 70 companies. . 5 Presentations & Business Lunch. . Job interview simulations. - AgroParisTech Ambassador for PwC